Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8

Rhea-AI Summary

Castle Biosciences, Inc. (CSTL) will release its financial results for Q2 and six months ending June 30, 2022, after market close on August 8, 2022. A conference call to discuss the results is scheduled for 4:30 p.m. Eastern Time on the same day. The webcast will be available on the company's Investor Relations page. Castle specializes in diagnostics, focusing on innovative tests for skin cancers and other conditions, with ongoing research in new test developments.

Positive

• Castle Biosciences is preparing to announce its Q2 and six-month financial results, which may include promising metrics.

Negative

• None.

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2022, after the close of market on Monday, Aug. 8, 2022.

Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.

Conference Call and Webcast Details

A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/949303499 or via the webcast link on the Investor Relations page of the Company’s website, https://ir.castlebiosciences.com/overview/default.aspx. Please access the webcast at least 10 minutes before the conference call start time. An archive of the webcast will be available on the Company’s website until Aug. 31, 2022.

To access the live conference call via phone, please dial 1 844 200 6205 from the United States, or +1 929 526 1599 internationally, at least 10 minutes prior to the start of the call, using the conference ID 705869.

There will be a brief Question & Answer session following management commentary.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005714/en/

Investor Contact:

Camilla Zuckero

czuckero@castlebiosciences.com

Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences, Inc.

FAQ

When will Castle Biosciences release its Q2 financial results?

Castle Biosciences will release its Q2 financial results on August 8, 2022, after market close.

What time is the conference call for Castle Biosciences' Q2 results?

The conference call for Castle Biosciences' Q2 results is scheduled for 4:30 p.m. Eastern Time on August 8, 2022.

How can I access the webcast for Castle Biosciences' financial results?

You can access the webcast for Castle Biosciences' financial results on the company's Investor Relations page or through the provided link in their press release.

What is the focus of Castle Biosciences' diagnostic tests?

Castle Biosciences focuses on diagnostic tests for skin cancers, uveal melanoma, Barrett's esophagus, and mental health conditions.